Follow
Fantastic — VERTIS-CV: Ertugliflozin’s CV outcomes trial confirms SGLT2i benefits https://www.mdedge.com/endocrinology/article/224137/diabetes/vertis-cv-ertugliflozins-cv-outcomes-trial-confirms-sglt2i #Cardiology #cardiologia #EchoFirst #cardiotwitter
